A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients with LIV-1-Positive Metastatic Breast Cancer

Diseases and Conditions Researched

Breast - Female

What is the purpose of this trial?

This study is being conducted to examine the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer, and to find the highest dose of the drug that can be given without unacceptable side effects. Other goals of the trial are to find out if SGN-LIV1A has any antitumor effects, to learn about the pharmacokinetics of SGN-LIV1A, and to explore the relationship between antigen expression and SGN-LIV1A effects.

Participation Guidelines

Age: 18 Years and older
Gender: Female

Click here for detailed participation information for this trial.

Sponsor: Seattle Genetics, Inc.
Last Updated:
Study HIC#: 1311013056